| dbo:abstract
|
- Gadofosveset (trade names Vasovist, Ablavar) is a gadolinium-based MRI contrast agent. It was used as the trisodium salt monohydrate form. It acts as a blood pool agent by binding to human serum albumin. The manufacturer (Lantheus Medical) discontinued production in 2017 due to poor sales. Gadofosveset facilitates high-resolution magnetic resonance angiography. Ferumoxytol (trade names Feraheme, Rienso), an intravenous iron-replacement therapy, has been shown to potentially be superior to gadofosveset as a blood pool agent for MR venography in pediatric patients. (en)
|
| dbo:alternativeName
| |
| dbo:casNumber
| |
| dbo:drugbank
| |
| dbo:fdaUniiCode
| |
| dbo:kegg
| |
| dbo:pubchem
| |
| dbo:thumbnail
| |
| dbo:wikiPageID
| |
| dbo:wikiPageLength
|
- 4052 (xsd:nonNegativeInteger)
|
| dbo:wikiPageRevisionID
| |
| dbo:wikiPageWikiLink
| |
| dbp:atcPrefix
| |
| dbp:atcSuffix
| |
| dbp:c
| |
| dbp:casNumber
| |
| dbp:chemspiderid
| |
| dbp:drugName
|
- Gadofosveset trisodium (en)
|
| dbp:drugbank
| |
| dbp:gd
| |
| dbp:h
| |
| dbp:iupacName
|
- Trisodium 2-{[-2-[bisamino]-3-[oxy-oxidophosphoryl]oxypropyl]-[2-[bisamino]ethyl]amino}acetate (en)
|
| dbp:kegg
| |
| dbp:legalUs
| |
| dbp:n
| |
| dbp:na
| |
| dbp:o
| |
| dbp:p
| |
| dbp:pregnancyUs
| |
| dbp:pubchem
| |
| dbp:routesOfAdministration
| |
| dbp:smiles
|
- [Gd+3].[Na+].[Na+].[Na+].[O-]CCNCCNC[C@@H]COPOC3CCCCC3.O (en)
|
| dbp:stdinchi
| |
| dbp:stdinchikey
|
- PIZALBORPSCYJU-QSQMUHTISA-H (en)
|
| dbp:tradename
| |
| dbp:unii
| |
| dbp:wikiPageUsesTemplate
| |
| dcterms:subject
| |
| gold:hypernym
| |
| rdf:type
| |
| rdfs:comment
|
- Gadofosveset (trade names Vasovist, Ablavar) is a gadolinium-based MRI contrast agent. It was used as the trisodium salt monohydrate form. It acts as a blood pool agent by binding to human serum albumin. The manufacturer (Lantheus Medical) discontinued production in 2017 due to poor sales. Gadofosveset facilitates high-resolution magnetic resonance angiography. Ferumoxytol (trade names Feraheme, Rienso), an intravenous iron-replacement therapy, has been shown to potentially be superior to gadofosveset as a blood pool agent for MR venography in pediatric patients. (en)
|
| rdfs:label
| |
| owl:sameAs
| |
| prov:wasDerivedFrom
| |
| foaf:depiction
| |
| foaf:isPrimaryTopicOf
| |
| foaf:name
|
- Gadofosveset trisodium (en)
|
| is dbo:wikiPageRedirects
of | |
| is dbo:wikiPageWikiLink
of | |
| is foaf:primaryTopic
of | |
